• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Surmodics Inc.

    11/20/25 4:06:14 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care
    Get the next $SRDX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)


    SURMODICS INC

    (Name of Issuer)


    Common Stock, $0.05 par value

    (Title of Class of Securities)


    868873100

    (CUSIP Number)


    DAVID GOLDMAN
    GAMCO INVESTORS, INC., ONE CORPORATE CENTER
    RYE, NY, 10580
    9149215000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    11/19/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GAMCO INVESTORS, INC. ET AL
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, HC



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GABELLI FUNDS LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, IA



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GAMCO Asset Management Inc.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, IA



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GABELLI & Co INVESTMENT ADVISERS, INC.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    IA, CO



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GGCP, INC.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    WYOMING
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, HC



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    Associated Capital Group, Inc.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, HC



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GABELLI MARIO J
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.05 par value
    (b)Name of Issuer:

    SURMODICS INC
    (c)Address of Issuer's Principal Executive Offices:

    9924 W 74TH ST, 9924 W 74TH ST, EDEN PRAIRIE, MINNESOTA , 55344.
    Item 2.Identity and Background
    (a)
    This statement is being filed by one or more of the following persons: GGCP, Inc. (GGCP), GGCP Holdings LLC (GGCP Holdings), GAMCO Investors, Inc. (GBL), Associated Capital Group, Inc. (AC), Gabelli Funds, LLC (Gabelli Funds), GAMCO Asset Management Inc. (GAMCO), Teton Advisors, LLC (Teton Advisors), Keeley-Teton Advisors, LLC (Keeley-Teton), Gabelli & Company Investment Advisers, Inc. (GCIA), Morgan Group Holding Co., (MGH), G.research, LLC (G.research), MJG Associates, Inc. (MJG Associates), Gabelli Securities International (Bermuda) Limited (GSIL), Gabelli Foundation, Inc. (Foundation), Mario Gabelli, LICT and CIBL. Those of the foregoing persons signing this Schedule 13D are hereinafter referred to as the Reporting Persons.
    (b)
    GAMCO is a New York corporation and GBL and MGH are Delaware corporations, each having its principal business office at One Corporate Center, Rye, New York 10580. GGCP is a Wyoming corporation and AC and GCIA are Delaware corporations each having its principal business office 191 Mason Street, Greenwich, CT 06830. GGCP Holdings is a Delaware limited liability corporation having its principal business office at 191 Mason Street, Greenwich, CT 06830. G.research is a Delaware limited liability company having its principal officers at One Corporate Center, Rye, New York 10580. Gabelli Funds is a New York limited liability company having its principal business office at One Corporate Center, Rye, New York 10580. Teton Advisors is a Wyoming limited liability company having its principal place of business at 189 Mason Street, Greenwich, CT 06830. Keeley-Teton Advisors is a Delaware limited liability company having its principal place of business at 141 W. Jackson Blvd., Chicago, IL 60604. MJG Associates is a Connecticut corporation having its principal business office at 191 Mason Street, Greenwich, CT 06830. The Foundation is a Nevada corporation having its principal offices at 165 West Liberty Street, Reno, Nevada 89501. LICT is a Delaware corporation having its principal place of business as 401 Theodore Fremd Avenue, Rye, New York 10580. CIBL, Inc. is a Delaware corporation having its principal place of business as 165 West Liberty Street, Suite 220, Reno, NV 89501.
    (c)
    GGCP makes investments for its own account and is the manager and a member of GGCP Holdings which is the controlling shareholder of GBL and AC. GBL, a public company whose stock is quoted on the OTCQX platform, is the parent company for a variety of companies engaged in the securities business, including certain of those named below. AC, a public company listed on the New York Stock Exchange, is the parent company for a variety of companies engaged in the securities business, including certain of those listed below. GAMCO, a wholly-owned subsidiary of GBL, is an investment adviser registered under the Investment Advisers Act of 1940, as amended (Advisers Act). GAMCO is an investment manager providing discretionary managed account services for employee benefit plans, private investors, endowments, foundations and others. GCIA, a wholly owned subsidiary of AC, is an investment adviser registered under the Advisers Act and serves as a general partner or investment manager to limited partnerships and offshore investment companies and other accounts. As a part of its business, GCIA may purchase or sell securities for its own account. GCIA or its relying advisers, act as a general partner or investment manager of a number of funds or partnerships, including Gabelli Associates Fund, L.P., Gabelli Associates Fund II, L.P., Gabelli Associates Limited, Gabelli Associates Limited II E, Gabelli Intermediate Credit Fund L.P., GAMA Select Plus Master Fund, Ltd., GAMCO Medical Opportunities L.P., and Gabelli Multimedia Partners, L.P. G.research is a wholly owned subsidiary of MGH. G.research, is a broker-dealer registered under the Securities Exchange Act of 1934, as amended (1934 Act), which may as a part of its business purchase and sell securities for its own account. Gabelli Funds, a wholly owned subsidiary of GBL, is a limited liability company. Gabelli Funds is an investment adviser registered under the Advisers Act which provides advisory services for The Gabelli Equity Trust Inc., The Gabelli Asset Fund, The Gabelli Growth Fund, The Gabelli Convertible and Income Securities Fund Inc., The Gabelli Value 25 Fund Inc., The Gabelli Small Cap Growth Fund, The Gabelli Equity Income Fund, The Gabelli ABC Fund, The Gabelli Global Content & Connectivity Fund, The Gabelli Gold Fund, Inc., The Gabelli Multimedia Trust Inc., The Gabelli Global Rising Income & Dividend Fund, The Gabelli Capital Asset Fund, The Gabelli International Growth Fund, Inc., The Gabelli Global Growth Fund, The Gabelli Utility Trust, The Gabelli Utilities Fund, The Gabelli Dividend Growth Fund, The Gabelli Focused Growth and Income Fund, The Comstock Capital Value Fund, The Gabelli Dividend and Income Trust, The Gabelli Global Utility & Income Trust, The GAMCO Global Gold, Natural Resources, & Income Trust, The GAMCO Natural Resources, Gold & Income Trust, The GDL Fund, Gabelli Enterprise Mergers & Acquisitions Fund, The Gabelli ESG Fund, Inc., The Gabelli International Small Cap Fund, The Gabelli Healthcare & Wellness Rx Trust, The Gabelli Global Small and Mid Cap Value Trust, Gabelli Merger Plus+ Trust Plc, The Gabelli Global Financial Services Fund, The Gabelli Global Mini Mites Fund, The Gabelli Media Mogul Fund, The Gabelli Pet Parents Fund, The Gabelli U.S. Treasury Money Market Fund, Bancroft Fund Ltd. and Ellsworth Growth & Income Fund Ltd., Gabelli Growth Innovators ETF, Gabelli Love Our Planet & People ETF, Gabelli Automation ETF, Gabelli Commercial Aerospace & Defense ETF, Gabelli Financial Services Opportunities ETF (collectively, the Funds), which are registered investment companies. Gabelli Funds is also the investment adviser to The GAMCO International SICAV (sub-funds GAMCO Merger Arbitrage and GAMCO All Cap Value), a UCITS III vehicle. Teton Advisors, an investment adviser registered under the Advisers Act, provides discretionary advisory services to The TETON Westwood Mighty Mites Fund, The TETON Convertible Securities Fund, The Teton Westwood Balanced Fund, and The TETON Westwood Equity Fund. The TETON Westwood Mighty Mites Fund and the Teton Convertible Securities Fund are subadvised by Gabelli Funds, and their holdings are included in this filing. Keeley-Teton, an investment adviser registered under the Advisers Act, provides discretionary advisory services to The Teton Westwood Smallcap Equity Fund, The Keeley Small Cap Dividend Value Fund, The Keeley Small-Mid Cap Value Fund, and The Keeley Mid Cap Dividend Value Fund, as well as to institutional and individual clients. MJG Associates provides advisory services to private investment partnerships and offshore funds. Mario Gabelli is the sole shareholder, director and employee of MJG Associates. MJG Associates is the Investment Manager of Gabelli International Limited and Gabelli Fund, LDC. Mario J. Gabelli is the general partner of Gabelli Performance Partnership, LP. The Foundation is a private foundation. Mario Gabelli is the Chairman, a Trustee and the Investment Manager of the Foundation. Elisa M. Wilson is the President of the Foundation. LICT is a holding company with operating subsidiaries engaged primarily in the rural telephone industry. LICT actively pursues new business ventures and acquisitions. LICT makes investments in marketable securities to preserve capital and maintain liquidity for financing their business activities and acquisitions and are not engaged in the business of investing, or trading in securities. Mario J. Gabelli is the Chief Executive Officer, a director, and substantial shareholder of LICT. CIBL is a holding company with interest in telecommunications operations, primarily in the rural telephone industry. CIBL actively pursues new business ventures and acquisitions. CIBL makes investments in marketable securities to preserve capital and maintain liquidity for financing their business activities and acquisitions and are not engaged in the business of investing, or trading in securities. Mario J. Gabelli is a director, and substantial shareholder of CIBL. Mario Gabelli is the controlling stockholder, co-Chief Executive Officer and a director of GGCP and Chairman and Chief Executive Officer of GBL. He is the Executive Chairman of AC. Mario Gabelli is also a member of GGCP Holdings. Mario Gabelli is the controlling shareholder of MGH and indirectly of Teton Advisors and Keeley-Teton Advisors.
    (d)
    Not applicable.
    (e)
    Not applicable.
    (f)
    United States.
    Item 4.Purpose of Transaction
     
    The Reporting Persons file the long form Schedule 13D pursuant to Section 13d-1 of the Securities Exchange Act of 1934 (the "Act") even though they may be technically eligible to file the short form Schedule G. Because the Reporting Persons may regularly communicate with the Issuer's management, filing the Schedule 13D ensures that these conversations are compliant with the reporting obligations under the Exchange Act.
    Item 5.Interest in Securities of the Issuer
    (a)
    As a result of the completion of the acquisition of the Issuer by an affiliate of GTCR LLC, the Reporting Persons no longer have beneficial ownership of any of the Issuer's shares.
    (b)
    Each of the Reporting Persons and Covered Persons has the sole power to vote or direct the vote and sole power to dispose or to direct the disposition of the Securities reported for it, either for its own benefit or for the benefit of its investment clients or its partners, as the case may be, except that (i) Gabelli Funds has sole dispositive and voting power with respect to the shares of the Issuer held by the Funds so long as the aggregate voting interest of all joint filers does not exceed 25% of their total voting interest in the Issuer and, in that event, the Proxy Voting Committee of each Fund shall respectively vote that Funds shares, (ii) at any time, the Proxy Voting Committee of each such Fund may take and exercise in its sole discretion the entire voting power with respect to the shares held by such fund under special circumstances such as regulatory considerations, and (iii) the power of Mario Gabelli, AC, GBL, and GGCP is indirect with respect to Securities beneficially owned directly by other Reporting Persons.
    (c)
    Information with respect to all transactions in the Securities which were effected during the past sixty days or since the most recent filing on Schedule 13D, whichever is less, by each of the Reporting Persons and Covered Persons is set forth below: DATE SHARES PURCHASED PRICE /SOLD ASSOCIATED CAPITAL GROUP, INC. 11/19/2025 -8,607 43.0000 11/18/2025 50 42.0300 11/14/2025 50 41.3910 11/14/2025 157 41.4418 11/13/2025 100 41.3969 11/12/2025 150 40.9820 11/11/2025 5,800 40.9126 GABELLI & COMPANY INVESTMENT ADVISERS, INC. GABELLI ASSOCIATES FUND II 11/19/2025 -15,208 43.0000 11/18/2025 100 42.0300 11/14/2025 50 41.3910 11/14/2025 300 41.4418 11/13/2025 100 41.3969 11/12/2025 200 40.9820 11/11/2025 700 40.9126 11/10/2025 -500 26.9733 GABELLI ASSOCIATES FUND 11/19/2025 -44,703 43.0000 11/18/2025 300 42.0300 11/14/2025 150 41.3910 11/14/2025 750 41.4418 11/13/2025 300 41.3969 11/12/2025 650 40.9820 11/11/2025 2,150 40.9126 11/10/2025 -1,650 26.9733 GABELLI ASSOCIATES LIMITED II E 11/19/2025 -27,459 43.0000 11/18/2025 250 42.0300 11/14/2025 50 41.3910 11/14/2025 450 41.4418 11/13/2025 200 41.3969 11/12/2025 400 40.9820 11/11/2025 1,300 40.9126 11/10/2025 -950 26.9733 GABELLI ASSOCIATES LIMITED 11/19/2025 -81,165 43.0000 11/18/2025 600 42.0300 11/14/2025 250 41.3910 11/14/2025 1,350 41.4418 11/13/2025 3,800 41.3969 11/12/2025 1,800 40.9820 11/10/2025 -3,400 26.9733 10/9/2025 -500 28.8256 10/2/2025 -500 30.0000 GABELLI FOUNDATION, INC. 11/17/2025 -3,000 42.8311 11/14/2025 -1,000 41.5500 11/13/2025 -6,000 41.3880 11/12/2025 -2,000 41.3204 11/11/2025 -2,000 40.9055 10/30/2025 1,000 26.8800 10/29/2025 1,000 27.2500 10/22/2025 1,000 28.2000 10/20/2025 500 28.0500 10/2/2025 500 29.9000 9/22/2025 200 32.1500 GABELLI FUNDS, LLC GABELLI ABC FUND 11/19/2025 -77,000 43.0000 11/18/2025 2,000 42.9697 11/17/2025 -25,000 42.8617 10/15/2025 3,000 27.6000 9/30/2025 2,000 29.9200 9/19/2025 800 32.3300 COMSTOCK CAPITAL VALUE FUND 11/19/2025 -3,250 43.0000 11/14/2025 250 41.4418 11/12/2025 250 40.9820 11/11/2025 250 40.9126 GABELLI ENTERPRISE M&A FUND 11/19/2025 -17,000 43.0000 11/18/2025 2,000 42.9697 11/17/2025 -15,000 42.8581 10/2/2025 500 29.9000 9/30/2025 300 29.9450 9/18/2025 300 32.0000 GABELLI MERCHANT PARTNERS PLC 11/19/2025 -18,000 43.0000 11/10/2025 -1,850 26.9733 11/10/2025 -1,000 27.5748 10/9/2025 -500 28.8256 10/2/2025 -500 30.0000 GAMCO MERGER ARBITRAGE UCITS 11/19/2025 -151,748 43.0000 11/18/2025 1,200 42.0300 11/14/2025 450 41.3910 11/14/2025 2,550 41.4418 11/13/2025 1,427 41.3969 11/12/2025 2,150 40.9820 11/11/2025 7,300 40.9126 11/10/2025 -350 26.9733 GDL FUND 11/19/2025 -41,700 43.0000 GABELLI SMALL & MIDCAP VALUE TRUST 11/19/2025 -3,700 43.0000 GABELLI HEALTHCARE & WELLNESS TRUST 11/19/2025 -10,000 43.0000 11/17/2025 -11,000 42.8647 11/12/2025 -4,000 41.4400 11/11/2025 -6,000 40.7277 11/10/2025 1,000 26.1788 10/24/2025 1,000 27.2633 10/23/2025 1,000 27.0959 GABELLI SMALL CAP GROWTH FUND 11/19/2025 -15,000 43.0000 11/17/2025 -4,500 42.8622 11/12/2025 -800 41.1000 GAMCO ASSET MANAGEMENT INC. 11/19/2025 -40,000 43.0000 11/18/2025 2,000 42.9700 11/17/2025 -60,000 42.8486 11/17/2025 -12,000 42.8650 11/12/2025 -6,000 41.1100 11/11/2025 -6,000 40.8157 10/31/2025 400 27.1500 10/27/2025 3,000 27.0500 10/22/2025 1,000 28.2500 10/3/2025 3,000 29.8000 9/23/2025 800 31.4000 GAMCO INVESTORS, INC. 11/19/2025 -100,000 43.0000 11/18/2025 100,000 42.9800 THE TRANSACTIONS ON 11/19/2025 ARE A RESULT OF THE COMPLETION OF THE ACQUISITION OF THE ISSUER BY AN AFFILIATE OF GTCR LLC.
    (e)
    The Reporting Persons ceased to be the beneficial owner of more than five percent of the Issuer on November 19, 2025.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    GAMCO INVESTORS, INC. ET AL
     
    Signature:PETER D. GOLDSTEIN
    Name/Title:CHIEF LEGAL OFFICER
    Date:11/20/2025
     
    GABELLI FUNDS LLC
     
    Signature:DAVID GOLDMAN
    Name/Title:GENERAL COUNSEL
    Date:11/20/2025
     
    GAMCO Asset Management Inc.
     
    Signature:DOUGLAS R. JAMIESON
    Name/Title:PRESIDENT
    Date:11/20/2025
     
    GABELLI & Co INVESTMENT ADVISERS, INC.
     
    Signature:DOUGLAS R. JAMIESON
    Name/Title:PRESIDENT
    Date:11/20/2025
     
    GGCP, INC.
     
    Signature:DAVID GOLDMAN
    Name/Title:ATTORNEY-IN-FACT
    Date:11/20/2025
     
    Associated Capital Group, Inc.
     
    Signature:PETER D. GOLDSTEIN
    Name/Title:CHIEF LEGAL OFFICER
    Date:11/20/2025
     
    GABELLI MARIO J
     
    Signature:DAVID GOLDMAN
    Name/Title:ATTORNEY-IN-FACT
    Date:11/20/2025
    Get the next $SRDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRDX

    DatePrice TargetRatingAnalyst
    11/14/2025Mkt Perform → Underperform
    Barrington Research
    3/7/2025$43.00Hold → Buy
    Lake Street
    6/13/2023$36.00Hold → Buy
    Needham
    2/13/2023Buy → Hold
    Needham
    2/4/2022$70.00 → $58.00Buy
    Needham
    11/10/2021$76.00 → $70.00Buy
    Needham
    9/8/2021$68.00 → $76.00Buy
    Needham
    More analyst ratings

    $SRDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today

    Surmodics, Inc. (NASDAQ:SRDX) ("Surmodics" or the "Company"), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it expects to close its previously announced acquisition (the "Merger") of the Company by an affiliate of GTCR LLC ("GTCR") promptly. In a joint status report filed with the United States District Court for the Northern District of Illinois (the "District Court"), the Federal Trade Commission ("FTC") and certain state regulators ("Plaintiffs") stated that they do not intend to appeal the November 10, 2025 ruling by the District Court denying the Plaintiffs' motion for a preliminary injunction to prevent the

    11/17/25 6:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR

    Surmodics, Inc. (NASDAQ:SRDX) ("Surmodics" or the "Company"), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the "District Court") has denied a request by the U.S. Federal Trade Commission (the "FTC") and certain state regulators to issue a preliminary injunction that would have prevented the Company and GTCR LLC ("GTCR") from consummating the proposed acquisition of the Company by an affiliate of GTCR (the "Merger"). Consummation of the Merger remains subject to a Temporary Restraining Order under which the parties to the Merger agree not to

    11/10/25 7:00:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations

    Analysis of the all-comers PROWL Registry demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients with symptomatic limb ischemia, over 40% of whom had symptoms lasting more than two weeks before intervention with the Pounce™ Platform. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL registry study were presented on November 3rd at an industry-sponsored session at the 23rd Annual VIVA Conference in Las Vegas, NV. PROWL natio

    11/4/25 6:15:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    SEC Filings

    View All

    SEC Form EFFECT filed by Surmodics Inc.

    EFFECT - SURMODICS INC (0000924717) (Filer)

    11/21/25 12:15:02 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Surmodics Inc.

    SCHEDULE 13D/A - SURMODICS INC (0000924717) (Subject)

    11/20/25 4:06:14 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Surmodics Inc.

    S-8 POS - SURMODICS INC (0000924717) (Filer)

    11/19/25 4:48:05 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $SRDX
    Financials

    Live finance-specific insights

    View All

    $SRDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SVP, Medical Device Coatings Olson Charles W returned 52,278 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - SURMODICS INC (0000924717) (Issuer)

    11/19/25 6:18:20 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    VP Finance, Corp. Controller Manders John D. returned 8,155 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - SURMODICS INC (0000924717) (Issuer)

    11/19/25 6:16:53 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Sr. VP of Legal, GC and Sec. Weber Gordon S. returned 21,040 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - SURMODICS INC (0000924717) (Issuer)

    11/19/25 6:15:41 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $29.6 million, an increase of 1% year-over-year GAAP loss of $(5.3) million, compared to $(7.6) million in the prior-year period Adjusted EBITDA(2) of $3.4 million, compared to $1.6 million in the pr

    8/8/25 7:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that third quarter of fiscal year 2025 financial results will be released before the market opens on Friday, August 8. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the third quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also

    8/6/25 4:05:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

    4/30/25 7:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics downgraded by Barrington Research

    Barrington Research downgraded Surmodics from Mkt Perform to Underperform

    11/14/25 11:19:52 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics upgraded by Lake Street with a new price target

    Lake Street upgraded Surmodics from Hold to Buy and set a new price target of $43.00

    3/7/25 8:21:43 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics upgraded by Needham with a new price target

    Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00

    6/13/23 7:48:05 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Leadership Updates

    Live Leadership Updates

    View All

    KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting

    6/27/23 7:05:00 AM ET
    $KRMD
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    11/14/24 3:36:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    11/6/24 1:30:21 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    10/23/24 10:43:41 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care